Bacampicillin: a new orally well-absorbed derivative of ampicillin.

Antimicrobial Agents and Chemotherapy
N O BodinB Sjöberg

Abstract

Bacampicillin (proposed international nonproprietary name), 1'-ethoxycarbonyloxyethyl 6-(d-alpha-aminophenylacetamido)penicillanate, is a new orally well-absorbed penicillin, highly active in vivo due to rapid transformation into ampicillin. The compound is stable in vitro at gastric pH and hydrolyzed slowly to ampicillin at neutral pH but very rapidly in the presence of biological fluids, e.g., tissue homogenates or serum. In vivo the transformation into ampicillin is so rapid that no unchanged compound could be detected in the blood after oral administration of bacampicillin to rats, dogs, and humans. On oral administration to mice, rats, and dogs, bacampicillin was found to be better absorbed than ampicillin, giving higher and earlier peak blood levels of ampicillin. The bioavailability of bacampicillin in rats and dogs was three to four times higher than that of an equimolar amount of ampicillin. On oral administration to rats, bacampicillin was found to give higher levels of ampicillin in organs such as the kidney, liver, and spleen than ampicillin itself. In "tissue cages" in rats, higher transudate levels of antibiotic were found after oral administration of bacampicillin than after ampicillin. On oral treatment of exper...Continue Reading

References

Jan 1, 1973·Advances in Pharmacology and Chemotherapy·G N Rolinson, R Sutherland
Mar 10, 1973·British Medical Journal·G D ChisholmL P Garrod
Aug 1, 1973·Antimicrobial Agents and Chemotherapy·W G GardnerR L Perkins
Jul 1, 1970·Journal of Medicinal Chemistry·W DaehneW O Godtfredsen
Mar 1, 1965·Journal of the Chemical Society·A B JANSEN, T J RUSSELL
Jun 1, 1974·Antimicrobial Agents and Chemotherapy·J P ClaytonH Ferres

❮ Previous
Next ❯

Citations

Jul 1, 1993·Agents and Actions·T J CartyA Weissman
Mar 5, 2003·Bioorganic & Medicinal Chemistry·Carsten Schultz
Dec 1, 1989·Journal of Veterinary Pharmacology and Therapeutics·C R Clarke
Feb 1, 1977·Antimicrobial Agents and Chemotherapy·H O HallanderJ Sjövall
Apr 1, 1977·Antimicrobial Agents and Chemotherapy·C CarbonS Lamotte-Barrillon
Jan 1, 1978·Antimicrobial Agents and Chemotherapy·J SjövallT Bergan
Jun 1, 1978·Antimicrobial Agents and Chemotherapy·T Bergan
Apr 1, 1979·Antimicrobial Agents and Chemotherapy·J S Tan, S J Salstrom
May 1, 1986·Antimicrobial Agents and Chemotherapy·A Saito, M Nakashima
Feb 19, 1983·British Medical Journal·A Dyas, R Wise
Jan 1, 1989·Genitourinary Medicine·C T LeeM Nadarajah
Jul 3, 2007·Biological & Pharmaceutical Bulletin·Masako OdaHiroshi Saitoh
Jan 1, 1979·Infection·E Bergogne-BerezinC Morel
Jan 1, 1979·Infection·A HeimdahlK Weilander
Jan 1, 1987·Drug Metabolism Reviews·F J Leinweber
Jun 10, 2011·Chemistry : a European Journal·Shuji WatanabeKazuya Kikuchi
Jun 22, 2010·Chemistry & Biodiversity·Sergio Martínez-RodríguezFrancisco Javier Las Heras-Vázquez
Jul 1, 1988·The Journal of Pharmacy and Pharmacology·N M Nielsen, H Bundgaard
Oct 1, 1979·Journal of Pharmacokinetics and Biopharmaceutics·M EhrneboL O Boréus
Jun 14, 2014·Journal of Medicinal Chemistry·Hervé PorasBernard P Roques
Jan 1, 1977·The Journal of International Medical Research·J Sjövall
May 11, 2017·Beilstein Journal of Organic Chemistry·S ArshadiE Ghorbani-Kalhor
Oct 12, 2018·Drug Development Research·Erik M Larsen, R Jeremy Johnson
Jan 1, 1981·Pharmacology & Therapeutics·R E Notari

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.